You are here

Our science / Clinical Trials / Find a Trial / NCT00630851

A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

Back to Search Print Save as PDF Bookmark Trial

NCT00630851

Last updated on February 23, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Akersberga, , 184 33 AKERSBERGA Sweden
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Probable or possible Alzheimer's disease

- Living in skilled nursing home

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Other types of dementia or psychiatric or neurologic disorders

- Musculoskeletal disease

NCT00630851
Pfizer
Completed
A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Alzheimer Disease
Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease
NCT00481520
All Genders
50+
Years
Multiple Sites
Alzheimer Disease
Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
NCT00479219
All Genders
18+
Years
Glendale, California
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
NCT00667810
All Genders
50+
Years
Multiple Sites
Alzheimer Disease
Single Ascending Dose Study of SRA-444 in Healthy Subjects
NCT00452504
Males
18+
Years
Zuidlaren,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now